二、本次交易的进展情况 2026 年 2 月 27 日，中国证券登记结算有限责任公司出具《证券过户登记确认书》， 本次交易已完成过户登记手续，过户日期为 2026 年 2 月 26 日。本次过户登记完成后， 广药二期基金持有南京医药 144,557,431 股无限售流通股，占南京医药目前总股本的 11.04%。 一、本次交易的基本情况 2025 年 9 月 26 日，广州白云山医药集团股份有限公司（"本公司"）召开第九届 董事会第二十九次会议，审议通过了《关于广州广药二期基金股权投资合伙企业（有 限合伙）收购南京医药股份有限公司 11.04%股份的议案》。本公司附属企业广州广 药二期基金股权投资合伙企业（有限合伙）（"广药二期基金"）拟以自有资金通过协 议转让方式收购Alliance Healthcare Asia Pacific Limited持有的南京医药集团股份有限 公司（原南京医药股份有限公司已更名为南京医药集团股份有限公司，简称"南京医 药"）144,557,431 股非限售股份（"目标股份"），占南京医药股份总数的 11.04%（"本 次交易"）。具体内容详见本公司于 2025 年 9 月 29 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出的。 茲刊載廣州白雲山醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(www.sse.com.cn)刊登的 本公司關於廣州廣藥二期基金股權投資合夥企業（有限合伙）收購南京醫藥集團股份有限公司11.04% 股份的進展公告之中文全文，僅供參考。 廣州白雲山醫藥集團股份有限公司 董事會 中國廣州，2026年2月27日 於本公告日，本公司董事會成員包括執行董事李小軍先生、陳傑輝先生、程寧女士、程洪進先生、 唐和平先生與黎洪先生，及獨立非執行董事陳亞進先生、黃民先生、黃龍德先生與孫寶清女士。 海外監管公告 一、本次交易的基本情况 证券代码：600332 证券简称：白云山 公告编号：2026－009 广州白云山医药集团股份有限公司 关于广州广药二期基金股权投资合伙企业（有限合伙） 收购南京医药集团股份有限公司 11.04%股份的进展公告 本 ...

来源：问董秘 投资者提问： 你好董秘，东方汽车采用了私有化h股，同时换成岚图汽车股份的方式。是因为股价未反应企业价值。 白云山的H股长期低于净资产，也是如此，是否能够采取如同东方汽车的方式，H股进行私有化，同时 换成王老吉的股份。样不仅能体现王老吉的价值，同时也有利于王老吉在全球拓展的影响力。 另外加 多宝谋求在港上市，而王老吉如果能在港上市，无疑是对加多宝的巨大打击。 董秘回答(白云山SH600332)： 尊敬的投资者您好，感谢您的关注和建议！ 查看更多董秘问答>> 免责声明：本信息由新浪财经从公开信息中摘录，不构成任何投资建议；新浪财经不保证数据的准确 性，内容仅供参考。 ...

编者按： 2026年全省高质量发展大会发出永争第一、不为人后的奋进号召，为广东在推进中国式现代化建设中走 在前列、谱写"中国式现代化看广东"的时代新篇注入强劲动力。2月25日马年开工第二天，广东省社会 科学界联合会与羊城晚报报业集团联合策划主办"广货行天下・社科一席谈"首场活动，华南农业大学罗 明忠、谭砚文，广东省农业科学院朱根发、余华荣，广东财经大学梁江川以及仲恺农业工程学院熊强等 专家，围绕广东土特产这一主题，从文化叙事、品牌标准化、特色品牌打造、渠道拓展、非遗赋能等多 个维度展开座谈。本期理论版特撷取座谈观点精粹，以飨读者。 接下来，"广货行天下・社科一席谈"还将围绕制造业、服务业等专题继续开展座谈，持续为"广货行天 下"献计出力，助力擦亮"广东制造""广东服务"双品牌，为广东在两业协同发展中向上突围、增创新优 势贡献社科力量。 聚力赋能"广货行天下" 社科界当有更大作为 □李宜航 "广货行天下"春季行动全面铺开，是广东聚力拼经济、奋力促发展的重要举措。全省社科界以高度的政 治站位、强烈的使命担当、精准的智力供给，在积极赋能"广货行天下"行动中，发挥了不可替代的作 用。乘势而上做实赋能工作，需要全省社科 ...

Core Viewpoint - The Guangdong Provincial High-Quality Development Conference emphasizes the theme of "coordinated development of manufacturing and service industries," aiming to stimulate economic growth and innovation in the region [1][2]. Group 1: Conference Highlights - The conference marks the fourth consecutive year of focusing on high-quality development, signaling that high-quality growth is a fundamental requirement rather than an option [2]. - The concept of "two-industry collaboration" is highlighted as a new direction for industrial development, particularly in the context of emerging technologies such as AI, biomanufacturing, and quantum communication [1][3]. Group 2: Company Initiatives - Guangzhou Pharmaceutical Group (广药集团) is actively pursuing modernization, technological advancement, digitalization, and internationalization to transform itself during the "14th Five-Year Plan" period [1][3]. - The company has made significant investments in technology innovation, establishing over 100 research platforms and engaging more than 25 dual-appointed academicians in the biopharmaceutical field [4][5]. Group 3: Strategic Goals - The company aims to become a technology-driven and innovative enterprise, moving beyond traditional pharmaceutical manufacturing to provide comprehensive health solutions [8]. - A commitment of 10 billion to 15 billion yuan in R&D investment is planned for the "14th Five-Year Plan" period, with an additional 20 billion to 30 billion yuan allocated for industrial investment and acquisitions [10]. Group 4: Market Expansion - The company plans to expand its international presence by targeting markets in Southeast Asia, the Middle East, and Europe, while also promoting its leading health beverage brand, WALOVI [11]. - The establishment of the Guangzhou Medical Device Export Comprehensive Service Platform exemplifies the "two-industry collaboration" approach, providing one-stop professional services for pharmaceutical enterprises [6].

Group 1 - Guangzhou Pharmaceutical Group has established a new capital company named Guangzhou Guangyao Capital Co., Ltd. with a registered capital of 2 billion yuan [1] - The business scope of the new company includes investment activities using its own funds and enterprise management consulting [1] - Guangzhou Guangyao Capital Co., Ltd. is wholly owned by Guangzhou Pharmaceutical Group Co., Ltd. [1]

Business Progress - The company announced on February 11, 2026, that its subsidiary Tianxin Pharmaceutical and its branch Baiyunshan Pharmaceutical Factory have 24 products, including Cefuroxime Sodium for Injection, proposed for selection in the national drug procurement program. The total sales revenue for these products is projected to be 798 million yuan in 2024, accounting for 1.06% of the company's revenue, and 550 million yuan in the first three quarters of 2025, accounting for 0.89% of revenue [1]. Subsidiary Development - On February 2 and 3, 2026, subsidiaries Guangzhou Baiyunshan Qixing Pharmaceutical Co., Ltd. and Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd. received changes to their drug production licenses from the Guangdong Provincial Drug Administration, involving new production addresses or adjustments to production workshops aimed at improving production efficiency. However, this is expected to have no significant impact on current financials [2]. Product R&D Progress - On February 6, 2026, the company's subsidiary Guangzhou Baiyunshan Xingqun Pharmaceutical Co., Ltd. successfully passed the consistency evaluation of quality and efficacy for its Alfacalcidol Soft Capsules, which are used to treat calcium metabolism disorders [3]. Funding Movements - According to data disclosed on February 5, 2026, JPMorgan Chase increased its holdings in Baiyunshan H-shares by 360,600 shares at approximately 18.85 HKD per share on January 30, 2026, raising its ownership stake to 9.12%. Additionally, the company emphasized in its Q3 2025 report that it would continue to promote its dividend policy and capital operations, but the timing of related events should be confirmed with the latest announcements [4].

Core Viewpoint - Li Zhaoting, the former richest man in Shijiazhuang, has been detained by the police, which has significant implications for his companies, particularly Dongxu Group and its subsidiaries [2][3][19]. Group 1: Company Overview - Dongxu Group Limited, the largest shareholder of Jinying Fund with a 66% stake, is controlled by Li Zhaoting [17]. - At his peak, Li Zhaoting controlled three listed companies: Dongxu Optoelectronics, Dongxu Blue Sky, and Jialinjie [20]. Group 2: Financial Misconduct - From 2015 to 2019, under Li Zhaoting's leadership, Dongxu Group engaged in extensive financial fraud, inflating revenues by 47.825 billion yuan and profits by 13.001 billion yuan [21]. - The highest single-year inflation of cash funds reached 44.79 billion yuan, and the group fraudulently issued corporate bonds worth 3.5 billion yuan in 2018 [21]. Group 3: Current Status and Future Implications - Following a series of upheavals, only Jialinjie remains as a listed company under the "Dongxu system" [23]. - Li Zhaoting's control over Jinying Fund is in jeopardy due to a lifetime ban from the securities market imposed by the China Securities Regulatory Commission in June 2025 [25]. - The shares of Jinying Fund held by Dongxu Group have been frozen multiple times by the court due to significant debt disputes [25].

Core Viewpoint - Guangzhou Pharmaceutical Group Co., Ltd. has disclosed significant anti-corruption results in a recent annual report, highlighting the company's commitment to integrity and governance [1] Group 1: Anti-Corruption Measures - The report details 17 cases of corruption over the past year, with a total amount involved of approximately 170 million yuan [1] - Internal sources indicate that these cases have been communicated internally as warnings to staff [1] Group 2: Disciplinary Actions - In 2025, the disciplinary inspection and supervision agencies of Guangzhou Pharmaceutical Group and its subsidiaries investigated 30 individuals and imposed 42 party disciplinary and administrative penalties [1] - The 17 typical cases involved key personnel from major subsidiaries, including Zhongyi Pharmaceutical, Wanglaoji Pharmaceutical, Baiyunshan Pharmaceutical Factory, He Jigong Pharmaceutical Factory, and Huanhong Traditional Chinese Medicine [1]

重要提醒！！！为防失联，请"星标"我们！进入无冕财经公众号，点击右上角"..."，再" "，以便您及时接收每篇推送~ wumiancaijing.com 最热的泛财经新闻，都在这儿了。 2月12日，广药集团纪律检查委员会发布文件，集中通报去年17起严重违纪违法典型案例，其中包括此前备受关注的广药集团腐败"窝案"。 文件通报的17起要案中，涉及广药集团旗下中一药业、王老吉药业、白云山制药总厂、何济公制药厂等多家核心子公司，涉案人职位上到董事长、总经 理、副总经理、部门总监、经理等各级管理人员，下至保卫科科长。腐败行为集中在药品原材料及包装材料采购、药品代理经销、广告投放与业务承揽、 款项结算、职务晋升等关键领域，部分人员还存在依托他人职权谋取私利、销售假药等严重违法行为，涉案总金额超2亿元。 ▲图片来自网络。 资讯整理：小冕 编辑：陈涧 设计：岚昇 广药集团腐败窝案15人被判刑 涉案超2亿，李楚源处理结果未出 本文由无冕财经（wumiancaijing）整理发布 从已披露的结果看，已有15人因受贿罪或销售假药罪被判处有期徒刑。其中，王老吉药业是被点名频次最高的企业，违法违纪行为涉及广药集团和王老吉 药业广告与媒 ...